🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/10/1998 | 12,44 | 12,53 | 12,13 | 12,50 | +0,50% | 3,27% | 186.000 |
| 22/10/1998 | 12,31 | 12,53 | 11,94 | 12,44 | +3,11% | 4,82% | 364.600 |
| 21/10/1998 | 12,50 | 12,56 | 12,00 | 12,06 | +0,26% | 4,50% | 425.000 |
| 20/10/1998 | 11,63 | 12,50 | 11,63 | 12,03 | +1,32% | 7,53% | 149.200 |
| 19/10/1998 | 11,38 | 12,00 | 11,38 | 11,88 | +2,70% | 5,49% | 161.600 |
| 16/10/1998 | 11,44 | 12,94 | 11,25 | 11,56 | +2,49% | 14,75% | 716.400 |
| 15/10/1998 | 10,50 | 11,44 | 10,50 | 11,28 | +6,49% | 8,93% | 150.400 |
| 14/10/1998 | 10,50 | 11,00 | 10,50 | 10,59 | -0,88% | 4,76% | 139.000 |
| 13/10/1998 | 11,56 | 11,56 | 10,50 | 10,69 | -8,56% | 9,19% | 238.800 |
| 12/10/1998 | 12,75 | 13,00 | 11,50 | 11,69 | -8,33% | 11,76% | 195.800 |
| 09/10/1998 | 11,44 | 13,00 | 11,19 | 12,75 | +13,33% | 15,85% | 344.600 |
| 08/10/1998 | 10,50 | 11,38 | 10,00 | 11,25 | +4,05% | 13,10% | 325.400 |
| 07/10/1998 | 10,94 | 11,00 | 10,63 | 10,81 | -0,57% | 3,43% | 137.600 |
| 06/10/1998 | 10,81 | 11,13 | 10,63 | 10,88 | +1,75% | 4,62% | 158.800 |
| 05/10/1998 | 11,50 | 11,69 | 10,56 | 10,69 | -8,80% | 9,78% | 388.200 |
| 02/10/1998 | 10,31 | 11,81 | 10,00 | 11,72 | +11,61% | 17,58% | 430.400 |
| 01/10/1998 | 11,19 | 11,25 | 10,50 | 10,50 | -8,70% | 6,70% | 692.200 |
| 30/09/1998 | 11,69 | 11,88 | 11,38 | 11,50 | -4,17% | 4,28% | 343.000 |
| 29/09/1998 | 12,13 | 12,31 | 11,25 | 12,00 | -2,54% | 8,76% | 351.600 |
| 28/09/1998 | 12,47 | 12,56 | 11,88 | 12,31 | +2,60% | 5,51% | 560.400 |
| 25/09/1998 | 12,00 | 12,13 | 11,38 | 12,00 | -3,03% | 6,25% | 468.600 |
| 24/09/1998 | 12,75 | 13,06 | 12,00 | 12,38 | -5,04% | 8,33% | 534.600 |
| 23/09/1998 | 13,63 | 13,72 | 12,81 | 13,03 | -6,08% | 6,65% | 600.400 |
| 22/09/1998 | 12,25 | 13,94 | 12,19 | 13,88 | +16,84% | 14,29% | 1.354.600 |
| 21/09/1998 | 10,78 | 12,06 | 10,50 | 11,88 | +5,85% | 14,49% | 742.400 |
| 18/09/1998 | 10,44 | 11,31 | 10,44 | 11,22 | +7,16% | 8,38% | 364.400 |
| 17/09/1998 | 9,59 | 10,88 | 9,50 | 10,47 | +6,69% | 14,33% | 308.000 |
| 16/09/1998 | 9,75 | 10,00 | 9,53 | 9,81 | +0,96% | 4,81% | 218.600 |
| 15/09/1998 | 9,19 | 9,75 | 9,16 | 9,72 | +3,67% | 6,46% | 212.200 |
| 14/09/1998 | 9,06 | 9,44 | 9,06 | 9,38 | +2,04% | 4,14% | 547.000 |